Literature DB >> 18320192

Management of cutaneous vascular complications in systemic scleroderma: experience from the German network.

Ilka Herrgott1, Gabriela Riemekasten, Nicolas Hunzelmann, Cord Sunderkötter.   

Abstract

Major cutaneous vascular complications of systemic sclerosis (SSc) are secondary Raynaud's phenomenon (RP) and digital ulcers. Even though SSc is a rare disease, timely and appropriate management of its vascular complications is mandatory for reducing the rate of major impairment. It should therefore be aware to physicians from different specialties. We evaluated the diagnostic and therapeutic approach toward secondary RP and ulceration in SSc patients at 28 German clinical centers at the time of initiation of the German network for Systemic Scleroderma (DNSS). We retrieved data via questionnaires and from the DNSS patient registry. Management of RP and ulcerations in SSc were heterogeneous at initiation of the network, reflecting a sometimes insufficient use of the diagnostic and therapeutic possibilities. As such, (1) calcium channel blockers were the first line therapy in most centers; but often in insufficient dosages, and (2) only 21.2% of patients with acral ulceration had received prostacyclins when recruited into the network. The sometimes insufficient care of vascular complications of SSc in Germany revealed the need for their standardized management, e.g. within a network for SSc and for consensus on a diagnostic or therapeutic algorithm.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18320192     DOI: 10.1007/s00296-008-0556-1

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  22 in total

Review 1.  Raynaud's phenomenon.

Authors:  J A Block; W Sequeira
Journal:  Lancet       Date:  2001-06-23       Impact factor: 79.321

Review 2.  [Raynaud phenomenon in dermatology : Part 2: therapy].

Authors:  C Sunderkötter; G Riemekasten
Journal:  Hautarzt       Date:  2006-10       Impact factor: 0.751

Review 3.  [Evidence-based therapy of Raynaud's syndrome].

Authors:  M Distler; J Distler; A Ciurea; D Kyburz; U Müller-Ladner; K Reich; O Distler
Journal:  Z Rheumatol       Date:  2006-07       Impact factor: 1.372

4.  Significance of anticentromere antibody in idiopathic Raynaud's syndrome.

Authors:  J Sarkozi; A A Bookman; P Lee; E C Keystone; M J Fritzler
Journal:  Am J Med       Date:  1987-11       Impact factor: 4.965

Review 5.  Vasoactive therapies in systemic sclerosis.

Authors:  G Riemekasten; C Sunderkötter
Journal:  Rheumatology (Oxford)       Date:  2006-10       Impact factor: 7.580

Review 6.  Pathophysiology and clinical consequences of Raynaud's phenomenon related to systemic sclerosis.

Authors:  C Sunderkötter; G Riemekasten
Journal:  Rheumatology (Oxford)       Date:  2006-10       Impact factor: 7.580

7.  Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis.

Authors:  A E Thompson; B Shea; V Welch; D Fenlon; J E Pope
Journal:  Arthritis Rheum       Date:  2001-08

8.  Outcomes in primary Raynaud phenomenon: a meta-analysis of the frequency, rates, and predictors of transition to secondary diseases.

Authors:  G Spencer-Green
Journal:  Arch Intern Med       Date:  1998-03-23

Review 9.  Management of Raynaud's phenomenon and digital ischemic lesions in scleroderma.

Authors:  Laura K Hummers; Fredrick M Wigley
Journal:  Rheum Dis Clin North Am       Date:  2003-05       Impact factor: 2.670

10.  Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.

Authors:  Peter A Merkel; Karen Herlyn; Richard W Martin; Jennifer J Anderson; Maureen D Mayes; Patrice Bell; Joseph H Korn; Robert W Simms; Mary Ellen Csuka; Thomas A Medsger; Naomi F Rothfield; Michael H Ellman; David H Collier; Arthur Weinstein; Daniel E Furst; Sergio A Jiménez; Barbara White; James R Seibold; Fredrick M Wigley
Journal:  Arthritis Rheum       Date:  2002-09
View more
  3 in total

Review 1.  The patient experience of Raynaud's phenomenon in systemic sclerosis.

Authors:  John D Pauling; Lesley Ann Saketkoo; Marco Matucci-Cerinic; Francesca Ingegnoli; Dinesh Khanna
Journal:  Rheumatology (Oxford)       Date:  2019-01-01       Impact factor: 7.580

2.  Registry evaluation of digital ulcers in systemic sclerosis.

Authors:  Felice Galluccio; Marco Matucci-Cerinic
Journal:  Int J Rheumatol       Date:  2010-08-25

3.  Raynaud's phenomenon and digital ischemia: a practical approach to risk stratification, diagnosis and management.

Authors:  Zsuzsanna H McMahan; Fredrick M Wigley
Journal:  Int J Clin Rheumtol       Date:  2010
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.